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Abstract
Iron metabolism and anemia may play an important role in multiple organ dysfunction syndrome in Coronavirus dis-
ease 2019 (COVID-19). We conducted a systematic review and meta-analysis to evaluate biomarkers of anemia and iron 
metabolism (hemoglobin, ferritin, transferrin, soluble transferrin receptor, hepcidin, haptoglobin, unsaturated iron-binding 
capacity, erythropoietin, free erythrocyte protoporphyrine, and erythrocyte indices) in patients diagnosed with COVID-
19, and explored their prognostic value. Six bibliographic databases were searched up to August 3rd 2020. We included 
189 unique studies, with data from 57,563 COVID-19 patients. Pooled mean hemoglobin and ferritin levels in COVID-19 
patients across all ages were 129.7 g/L (95% Confidence Interval (CI), 128.51; 130.88) and 777.33 ng/mL (95% CI, 701.33; 
852.77), respectively. Hemoglobin levels were lower with older age, higher percentage of subjects with diabetes, hyperten-
sion and overall comorbidities, and admitted to intensive care. Ferritin level increased with older age, increasing proportion 
of hypertensive study participants, and increasing proportion of mortality. Compared to moderate cases, severe COVID-19 
cases had lower hemoglobin [weighted mean difference (WMD), − 4.08 g/L (95% CI − 5.12; − 3.05)] and red blood cell count 
[WMD, − 0.16 × 1012 /L (95% CI − 0.31; − 0.014)], and higher ferritin [WMD, − 473.25 ng/mL (95% CI 382.52; 563.98)] and 
red cell distribution width [WMD, 1.82% (95% CI 0.10; 3.55)]. A significant difference in mean ferritin levels of 606.37 ng/
mL (95% CI 461.86; 750.88) was found between survivors and non-survivors, but not in hemoglobin levels. Future studies 
should explore the impact of iron metabolism and anemia in the pathophysiology, prognosis, and treatment of COVID-19.
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Introduction
Infection with severe acute respiratory syndrome coronavi-
rus 2 (SARS-COV-2) often results in Coronavirus disease 
2019 (COVID-19), a disease that endangers disproportion-
ately the elderly, those with pre-existing chronic conditions 
such as cardiovascular disease, diabetes mellitus and hyper-
tension [1, 2]. If deteriorating, COVID-19 can lead to sep-
sis, septic shock, and multiple organ dysfunction syndrome, 
with mechanical ventilation or extracorporeal membrane 
oxygenation having low therapeutic efficacy [3]. The patho-
physiological background underlying deterioration and low 
efficacy of common treatments is unclear.
Most patients with COVID-19 who require intensive care 
will develop an atypical form of the acute distress respira-
tory syndrome (ARDS) with preserved lung gas volume [4], 
suggesting hypoxia due to physiological processes other 
than alveolar dysfunction may play a role in the progno-
sis of the disease [5]. Disturbed iron metabolism may be 
one such affected process. Indeed, recent data show that 
COVID-19 patients tend to present decreased hemoglobin 
levels indicating the presence of anemia, and pathologi-
cally increased levels of ferritin. A study of 67 COVID-19 
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patients in Singapore reported that during their course in 
an intensive care unit (ICU), patients developed more pro-
found and significantly lower hemoglobin levels, compared 
to patients not admitted to ICU [6]. Another study in elderly 
patients hospitalized for COVID-19 found that most patients 
had hemoglobin levels lower than the normal range, but 
did not find significant differences in hemoglobin levels 
between survivors and non-survivors. However, follow-up 
was incomplete for half of the patients [7]. In a report of 
5700 patients hospitalized for COVID-19 in the New York 
City area, ferritin levels were pathologically high, a find-
ing in line with previous studies from China [8, 9]. Both 
anemia and hyperferritinemia, regardless of the underlying 
pathology, are strong predictors of mortality [10, 11]. Ane-
mia could be the result of iron-restricted erythropoiesis aris-
ing from alterations in iron metabolism. Increased ferritin 
levels could be indicative of a strong inflammatory reac-
tion in COVID-19 or related to viral entry into the human 
body and its impact on iron metabolism [12, 13]. Iron is an 
essential micronutrient for both humans and pathogens [14]. 
The innate immune response could restrict iron availability 
during infections to deprive the pathogen of it, a mechanism 
that would also lead to anemia [15, 16]. Anemia, in turn, 
reduces oxygen delivery to the tissue and may thus play an 
important role in the development of multi-organ failure. 
Therefore, it is crucial to understand the relation between 
anemia, iron metabolism and progression of COVID-19, and 
whether these associations differ by age, sex and presence 
of chronic conditions.
We conducted a systematic review and meta-analysis of 
available observational evidence to (i) quantify the mean 
levels of hemoglobin, ferritin and other biomarkers of iron 
metabolism, and of biomarkers related to erythrocyte indices 
in COVID-19 patients, (ii) explore whether the levels would 
differ by age, sex presence of chronic conditions and severity 
of COVID-19, and (iii) whether these biomarkers could have 
clinical and/or prognostic utility in COVID-19.
Methods
We conducted a systematic review and meta-analysis accord-
ing to a recently published guideline and reported accord-
ing to PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) guidelines [17]. The protocol 
was registered in PROSPERO (CRD42020180670) and is 
available at https ://www.crd.york.ac.uk/prosp ero/displ ay_
recor d.php?Recor dID=18067 0.
Data source and strategy
We searched MEDLINE (National Library of Medicine, 
US), EMBASE (Elsevier, Netherlands), Web of Science 
(Clarivate Analytics, US), Cochrane (Cochrane Collabo-
ration, UK), the WHO COVID-19 database and Google 
Scholar (Google, Inc., US) to identify relevant articles. 
We used search terms related to COVID-19 infection and 
SARS-CoV-2 virus, and several markers of anemia and iron 
storage and metabolism, including hemoglobin, ferritin, 
transferrin, soluble transferrin receptor, hepcidin, hapto-
globin, unsaturated iron-binding capacity, erythropoietin, 
free erythrocyte protoporphyrin, red blood cell count (RBC), 
red cell distribution width (RDW), red cell volume (RCV), 
mean corpuscular volume (MCV), mean corpuscular hemo-
globin (MCH), mean corpuscular hemoglobin concentration 
(MCHC), reticulocyte count, and reticulocyte index. We 
also included search terms related to clinical progression 
of COVID-19, such as prognosis, severity, ICU admission, 
mortality, risk factors, clinical features, clinical character-
istics or predictors. We searched the databases from incep-
tion until August 3rd 2020. We limited our search to human 
studies and restricted our analysis to articles published in 
English. The detailed search strategies are presented in 
eAppendix 1.
Study selection and eligibility criteria
All observational studies (e.g., cross-sectional, cohort, and 
case–control studies), except for case reports and case-series, 
were included. We included studies that reported on the lev-
els of the biomarkers of iron metabolism, erythropoietin and 
erythrocyte indices, hemoglobin levels or the prevalence of 
anemia among COVID-19 patients, or their levels by the 
clinical outcome of patients with COVID-19. Outcomes of 
interest include disease severity, admission to intensive care 
unit, mechanical ventilation, and mortality across all age 
groups. Studies examining the association between the bio-
markers and risk of COVID-19 complications (e.g., admis-
sion to intensive care unit, death) were also included. Studies 
conducted in pregnant women and individuals with cancer 
were excluded.
Data extraction
Two independent reviewers screened the titles and abstracts 
according to the selection criteria. We recorded data on the 
author’s name, digital object identifier, study location, study 
design, sample size, demographic and clinical characteris-
tics, laboratory results, disease severity, and outcome in a 
data extraction form. The form was developed, piloted, and 
discussed within the review group before full data extraction. 
All laboratory values were extracted as reported and then 
converted to conventional units based on the US National 
Institute of Standards and Technology conversion factors. 
For studies reporting only median and ranges (interquartile 
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range, range, and maximum-minimum values), we converted 
these values into mean and standard deviation [18].
Risk of bias assessment
The quality of included studies was assessed by two authors 
independently using the Newcastle–Ottawa Scale for 
case–control, cross-sectional and cohort studies, as appli-
cable [19]. A third author adjudicated in case consensus was 
not reached. The scale was developed for non-randomized 
and observational studies and assessed quality in three broad 
categories, namely, selection of study groups/participants, 
comparability of the study groups/participants, and the 
assessment of exposure/outcome of interest. Quality was 
assessed on a 10-point scale and classified as good quality 
(9–10 points), fair quality (6–8), and poor quality (< 6).
Data synthesis and analysis
Based on the extracted data of each study, we computed 
pooled means and standard deviations for each biomarker 
and anemia prevalence for all COVID-19 patients, and 
weighted mean difference in levels of biomarkers between 
severe versus moderate cases, and survivors versus non-sur-
vivors. For the adult population, anemia was defined accord-
ing to World Health Organization (WHO) guidelines (hemo-
globin levels for males < 130 g/L and females < 120 g/L). We 
pooled mean difference by using a random-effects model. 
Heterogeneity was quantified using the  I2 statistic [20]. 
Country of the study, age-group (pediatric vs. adult), the 
mean age of the study population, gender distribution, per-
centage of comorbidities, and proportion of patients admit-
ted to ICU were pre-specified as characteristics for assess-
ment of heterogeneity and were evaluated using stratified 
analyses and univariate random effects meta-regression. 
To decrease the risk of double-reporting of patients, we 
did sensitivity analyses by (i) randomly excluding 20% of 
the included studies in the meta-analysis and (ii) excluding 
studies from the Asia Pacific region. Publication bias were 
appraised using funnel plots and Egger’s test for assessing 
asymmetry. We used STATA 15.1 (Statacorp, Texas, US, 
2017) for all the analyses. All analyses were done using 
2-tailed tests with a p-value < 0.05 considered statistically 
significant.
Results
Study identification and selection
3,601 unique citations were identified, of which 648 were 
selected for full-text evaluation. Of those, under full-text 
evaluation, 189 observational studies comprising 57,563 
COVID-19 patients were included for the final analysis. 
References of the included studies can be found in the Sup-
plemental Material, and the flow chart of study selection 
results can be found in Fig. 1. In brief, the majority of the 
studies were conducted in the Asia Pacific region (n = 134, 
72%), with 21, 20 and 14 studies coming from Europe, the 
US, and Middle-East, respectively. No study was found in 
South America. The majority of the studies were conducted 
in adults (n = 159, 84.13%), 22 studies (11.64%) included 
both pediatric and adult patients, and 8 studies (4.23%) 
included pediatric patients only. The mean age of study 
patients ranged from 2.5 to 75.25 years. The proportion of 
males ranged from 0 to 100%. Detailed characteristics of 
the included studies can be found in Supplemental Table S1.
Serum hemoglobin levels
Due to heterogeneity among studies, we were not able to 
provide a pooled estimate on prevalence of anemia among 
Covid-19 patients. Based on findings from 139 observa-
tional studies comprising 40,450 individuals, pooled mean 
hemoglobin level was 129.7 g/L (95% Confidence Interval 
(CI) 128.51; 130.88; I2 = 98.2%, P-value for heterogene-
ity < 0.001, Table 1). In the subgroup analyses, mean hemo-
globin levels were lower in studies including subjects above 
median age (55.25 years) and having a higher proportion of 
male participants, prevalent cardiovascular disease, diabetes 
and hypertension, and a higher proportion of ICU admission 
(Supplementary Table S2). Similarly, when fitting regression 
lines, significant linear trends were observed for mean hemo-
globin levels decreasing with advancing mean age of study 
participants, increasing proportion of subjects with diabetes, 
hypertension and overall comorbidities in each study (Sup-
plemental Figure S7). Compared to moderate COVID-19 
cases (using data from 63 studies with 21,605 individuals), 
severe cases had lower hemoglobin levels [weighted mean 
difference (WMD), − 4.08  g/L (95% CI − 5.12; − 3.05); 
I2 = 59%, P-value for heterogeneity < 0.001] (Table 2, Sup-
plemental Figure S1). The mean difference was larger in 
studies with a higher proportion of individuals with hyper-
tension (Supplemental Table S3). In addition, we observed a 
lower mean difference in hemoglobin levels between severe 
and moderate COVID-19 cases with an increasing number 
of proportion of study participants with diabetes (Supple-
mental figures S8). Based on pooled estimates from 27 stud-
ies, we did not find a significant difference in hemoglobin 
levels between COVID-19 survivors and non-survivors 
[WMD, − 0.26 g/L (95% CI − 2.37; 1.85); I2 = 74%, P-value 
for heterogeneity < 0.001] (Table 2, Supplemental Figure 
S2). In subgroup analyses, none of the patient characteristics 
were identified as a source of heterogeneity (Supplemen-
tal Table S4). However, when fitting a regression line, the 
WMD of mean hemoglobin levels between survivors and 
 P. E. Taneri et al.
1 3
non-survivors decreased with a higher percentage of diabetic 
patients in each study (Supplemental figures S9).
Among studies included in the narrative synthesis, Huang 
et al. [21] reported reduction in hemoglobin levels in 38.2% 
of hospitalized COVID-19 patients, but did not specify the 
definition of decreased hemoglobin. While Wang et al. [1] 
reported reduced hemoglobin levels (< 110 g/L) in 19.23% 
of the study population admitted to hospital. In contrast, Xu 
et al. [22] studied asymptomatic patients and reported none 
of the cases had decreased hemoglobin levels, albeit, not 
defining the cut-off of decreased levels. Based on retrospec-
tive data from 245 individuals with COVID-19, Liu et al. 
[23] found that the unadjusted association between baseline 
hemoglobin levels and all-cause mortality during hospi-
talization was non-significant, and the odds ratio of death 
with increasing serum hemoglobin level was 0.98 (95% CI 
0.96, 1.00, p = 0.05). Cai et al. [24] studied factors associ-
ated with ICU admission and found no link between hemo-
globin levels and odds of being admitted at ICU. In a study 
by Cen et al. [25] hemoglobin levels below 110 g/L were 
linked with disease progression in patients with COVID-
19; univariable hazard ratio was 3.91 (95% CI 2.99–5.10). 
In addition, Giacomelli et al. [26] reported anemia (defined 
as hemoglobin levels below 125 g/L) was more prevalent 
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in Covid-19 non-survivors (66.7%) compared to survivors 
(42.7%).
Serum ferritin levels
Based on findings from 54 observational studies, includ-
ing 24,262 COVID-19 patients, pooled mean ferritin level 
in COVID-19 patients was 777.33 ng/mL (95% CI 701.33; 
852.77), I2 = 95.5%, P-value for heterogeneity < 0.001 
(Table 1). In subgroup analyses, mean pooled ferritin levels 
were higher in studies including older population, higher 
proportion of hypertensive patients and of patients who did 
not survive (Supplementary Table S5). In addition, when 
regressing the most important study participants character-
istic against mean serum ferritin levels, we observed signifi-
cant linear trends with mean serum ferritin levels increasing 
with advancing age, increasing proportion of male study par-
ticipants, number of hypertensive patients and proportion of 
patients admitted to ICU (Supplemental figures S10).
Based on pooled estimates from 29 studies and 13,620 
individuals, the mean difference in serum ferritin was higher 
in severe COVID-19 individuals compared to moderate 
cases; [WMD, 473.25 ng/mL (95% CI 382.52; 563.98); 
I2 = 91.8%, P-value for heterogeneity < 0.001] (Table 2, 
Supplemental figure S3). Similarly, when pooling the esti-
mates from 18 observational studies and 7,190 individu-
als we found higher mean ferritin levels in non-survivors 
as compared to survivors [ WMD, 606.37 ng/mL (95% 
CI 461.86; 750.88); I2 = 90.9%, P-value for heterogene-
ity < 0.001] (Table 2, Supplemental figure S4). In subgroup 
analyses concerning disease severity and survival, high het-
erogeneity between the studies was not explained by any of 
studied patient’s characteristics. We observed a linear trend 
with WMD of ferritin levels between severe and moderate 
COVID-19 cases increasing with advancing age, while no 
linear trends were observed between patients characteris-
tics and WMD in ferritin levels among survivors and non-
survivors (Supplemental Table S6&7, Supplemental figure 
S11 & 12).
In line with our findings, Zhou et al. found in a univari-
able analysis that odds of in hospital death were higher 
among patients with ferritin levels above 300 ng/mL com-
pared to those with serum ferritin ≤ 399 ng/mL( odds ratio 
was 9.10 (95% CI 2.04; 40.58, p = 0.0038). Indeed, levels of 
serum ferritin were elevated in non-survivors compared with 
survivors (562 ng/mL ± 492 ng/mL) throughout the clinical 
course, and were increased with disease deterioration [3]. 
Similarly, in a study by Li et al. [27] ferritin was significantly 
higher in severe cases. Shah et al. reported no significant 
differences in serum ferritin levels and transferrin saturation 
between patients with non-severe versus severe hypoxemia. 
Yet, in patients with severe hypoxemia they reported signifi-
cantly lower levels of serum iron [median 2.3 μmol/L (IQR, 
2.2–2.5)] in comparison to non-severe hypoxemia (median 
4.3 μmol/L. (IQR, 3.3–5.2)] [28].
Other biomarkers
We were able to pool the estimates from 13 and 4 studies on 
mean RBC and RDW comprising 1,382 and 1,538 subjects 
and the pooled mean RBC level and RDW were 4.09 × 1012/L 
(95% CI 3.9; 4,28) and 12.99% (95% CI 12.62;13.36) respec-
tively. In addition, based on seven, five and three observa-
tional studies, pooled MCV, MCH and MCHC were 89.88 fL 
(95% CI 88.05; 91.75), 38.68 pg (95% CI 30.17;31.18) and 
338.05 g/dL (95% CI 332.08; 344.03) respectively (Table 1, 
Supplemental Figure S5). Due to limited number of studies, 
we were able to perform meta-regression only for analyses 
concerning RBC. In subgroup analyses, mean RBC count 
was lower in studies including higher proportion of patients 
with comorbidities (73.2%); in line with this, with increasing 
proportion of subjects with comorbidities, RBC count was 
decreasing (Supplemental table S8 and Supplemental figure 
S13). When pooling the estimates from seven observational 
studies and 717 individuals with COVID-19, the mean dif-
ference in RBC count was lower in individuals with severe 
as compared to moderate disease [WMD, − 0.16 × 1012/ 
(95% CI − 0.31; − 0.014)], while RDW was higher [WMD, 
1.82% (95% CI 0.10; 3.55] (Table 2, Supplemental Figure 
S6). We were not able to meta-analyze the other biomarkers 
of iron metabolism and anemia due to limited number of 
studies included in current review and/or high heterogeneity 
in reporting across the studies.
Quality of studies and publication bias
The majority of studies included in the current systematic 
review were evaluated as low risk of bias (n = 114, 60.3%), 
while the rest of the studies were evaluated as medium risk 
of bias (n = 75) (Supplemental table S1 and S9). The funnel 
plot on ferritin difference between survivors and non-survi-
vors was asymmetrical and Egger’s P value was 0.002 sug-
gesting the presence of publication bias, while for the rest of 
the meta-analyses including 5 or more studies we found no 
evidence of publication bias (Supplemental figures S14-16).
Discussion
To the best of our knowledge, the current study is the first 
updated and comprehensive systematic review and meta-
analyses acknowledging the potential clinical utility of ane-
mia and iron metabolism in COVID-19. Based on data from 
189 studies and 57,563 COVID-19 patients across all ages, 
we found a pooled mean hemoglobin level of 129.7 g/L, 
which decreased with older age and a higher proportion of 
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comorbid illness and disease severity. We also found patho-
logical values of ferritin in most patients, a finding more 
prominent in males, elderly and individuals with hyper-
tension. Major differences in ferritin levels were reported 
between different levels of severity, and among patients 
who survived and those who did not. In addition, compared 
to moderate COVID-19 cases, severe patients had lower 
RBC count and higher RDW. Due to limited evidence and/
or heterogeneity among included studies, we were not able 
to meta-analyze the evidence on other biomarkers of iron 
metabolism and anemia.
The mean level of hemoglobin in COVID-19 patients 
across all ages in this review represents a value for ane-
mia diagnosis in men as defined by WHO (< 130 g/L), with 
anemic mean levels observed in the elderly, and for severe 
cases. Indeed, a study in 339 hospitalized elderly COVID-19 
patients found that the majority of patients had mean values 
of hemoglobin lower than normal [7]. However, most of the 
studies did not report hemoglobin levels by sex, and none 
of the studies reported the prevalence of anemia based on 
age and sex-specific WHO cut-offs. Thus, it was challenging 
to provide an accurate picture of the burden of anemia in 
COVID-19 patients. The SASR-CoV-2 infection is associ-
ated with high mortality, especially among the elderly over 
the age of 65 + and comorbid patients.
Hemoglobin concentration is one of the most important 
determinants of the oxygen-carrying capacity of the blood. 
Low hemoglobin in COVID-19 patients, especially on popu-
lations at risk of complications and mortality, could indicate 
that the patients could suffer from a decreased capability 
of hemoglobin to support the increased peripheral tissue 
demands for oxygen due to the hyper-metabolic states dur-
ing infection. Indeed, significant complications of COVID-
19 patients are septic shock and multiple organ dysfunction 
syndrome, with mechanical ventilation or extracorporeal 
membrane oxygenation having low efficacy in mitigat-
ing its impact and progression [3]. While viral sepsis is 
often ignored in the clinical diagnosis, studies have shown 
COVID-19 patients to have developed sepsis, leading to sub-
sequent multiple organ dysfunction and admission to ICU 
[29, 30]. According to recent evidence, COVID-19 patients 
do experience an atypical form of the acute distress respira-
tory syndrome with preserved lung gas volume [4], suggest-
ing that the prognosis could depend on the ability of the 
human body to meet the oxygen demands of the peripheral 
tissues, which, if not met, may lead to hypoxia and ischemia. 
Studies have reported that anemia is associated with 2.6 
times increased risk of mortality in chronic obstructive pul-
monary diseases; the overall 90-day mortality among these 
patients with acute respiratory failure treated with invasive 
mechanical ventilation was 57.1% versus 25% in non-anemic 
patients [31, 32]. A previous meta-analysis has shown that 
among a mixed population, independent of sex, age and 
cardiovascular diseases, anemia is associated with a 41% and 
33% increased risk of all-cause mortality and cardiovascular 
mortality, respectively [11]. A similar risk of mortality was 
also shown in two other meta-analyses comparing heart fail-
ure patients with and without anemia, or stroke patients with 
and without anemia [33, 34]. Also, another meta-analysis 
has shown that lower baseline hemoglobin values in heart 
failure patients are associated with increased crude mortality 
rates (r =  − 0.396, p = 0.025) [33]. In this meta-analysis we 
show that the severity of disease and prognosis of patients 
with COVID-19 might depend on lower hemoglobin levels 
as severe cases had significantly lower hemoglobin levels 
than moderate cases. Future prospective studies with com-
plete follow-up are needed to confirm the impact of anemia 
in COVID-19 outcomes, and whether the incidence of low 
hemoglobin levels does predict mortality in these patients.
A striking finding of this meta-analysis is the pathological 
value of ferritin among COVID-19 patients, with significant 
differences between severe and moderate cases, and survi-
vors and non-survivors. Ferritin is known to be elevated in 
inflammatory conditions, with hyperferritinemia being a 
key acute-phase reaction used by clinicians as a marker for 
therapeutic response [12]. However, recent studies suggest 
that increased levels of circulating ferritin levels may not 
only reflect an acute-phase response, but also play a critical 
role in inflammation by contributing to the development of 
a cytokine storm [12]. According to Shoenfeld et al. [35] the 
clinical picture of the critical cases of COVID-19 resembles 
macrophage activating syndrome, which is commonly asso-
ciated with high levels of ferritin or even a cytokine storm. 
H-chain of the ferritin could be important in activating mac-
rophages to increase the secretion of inflammatory cytokines 
observed in COVID-19 patients [35]. Another explanation 
for the increased levels of ferritin could be the role of iron 
metabolism in supporting the innate immune system to 
fight invading microorganisms. The innate immune system 
orchestrates control over iron metabolism as a response to 
viral infections. For viral replication, enhanced cellular 
metabolism and optimal iron levels within host cells are 
necessary [13, 36]. Therefore, the innate immune system 
will react by decreasing the bioavailability of iron to limit 
the replication of the virus during the acute phase of infec-
tion. In these conditions, through interleukin-6 and Toll-
like-receptor-4 dependent pathways, the levels of the liver-
derived iron hormone hepcidin-the master regulator of iron 
homeostasis- could increase and block, the activity of the 
transporter ferroportin which carries iron out of the cells, 
and therefore decrease the amount of iron absorbed from the 
diet, causing cellular sequestration of iron (i.e., principally in 
hepatocytes, enterocytes, and macrophages) [36]. Increased 
intracellular iron sequestration will lead to an upregulation 
of cytosolic ferritin, which sequesters and stores iron to pre-
vent iron-mediated free radical damage [36]. The increased 
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retention and storage of iron within ferritin in macrophages 
contribute to the characteristic fall in serum iron concen-
trations and an increase in serum ferritin concentrations as 
observed in an acute phase response [37]. The net result will 
be a diminished iron availability for erythropoiesis and as 
a result further aggravation of anemia. This is in line with 
our findings showing the worst erythrocyte phenotypes in 
severe COVID-19 patients compared to non-severe cases. 
Also, high ferritin levels and/or anemia could be second-
ary to baseline haemoglobinopathies such as alpha thalas-
semia, which is highly prevalent in Chinese population (up 
to 7.8%), from which most of our studies were derived [38, 
39]. Regardless of the etiology (Fig. 2), serum ferritin is 
highly elevated in patients with COVID-19, and it seems 
warranted to assess whether serum ferritin could be used as 
a screening biomarker for the severity of the inflammatory 
state that patients with COVID-19 have.
Our systematic review highlights important gaps in the 
role of iron biomarkers other than ferritin in the progno-
sis of COVID-19. Of the included iron status parameters, 
only information on ferritin levels was available. Future 
studies should also measure other iron status parameters to 
establish whether iron-restricted erythropoiesis is inflicting 
anemia, and whether anemia is contributing to poor out-
comes. Assessing the other stated parameters and interpret-
ing them with respect to iron status in the setting of inflam-
mation will be a challenging task. Therefore, the inclusion 
of soluble transferrin receptor (sTfR) could be of additive 
value for iron-restricted erythropoiesis, as elevated levels 
of sTfR reflect both erythroid activity and functional iron 
deficiency. The markers are known to be less affected by 
concomitant chronic disease or inflammation. Future pro-
spective population-based and clinical studies are necessary 
to investigate the utility of using levels of hemoglobin levels 
and iron biomarkers for risk stratification and to identify 
patients who could benefit from early prevention strategies. 
Provided that anemia and altered iron metabolism play a role 
in COVID-19, public health strategies may be designed to 
protect this population that could be at risk of COVID-19 
complications.
This study has several limitations. First, considering we 
restricted our review to articles in English, we cannot rule 
out publication bias, which could limit our overall findings. 
Second, the interpretation of the findings should be based 
Fig. 2  The potential role of red blood cell dynamics and iron homeo-
stasis in the clinical presentation of COVID-19. The figure shows two 
potential pathways through which iron metabolism may be involved 
in the pathophysiology of COVID-19. Pathway 1: the virus inflicts 
hypoxia via direct deleterious effects on the respiratory system, alter-
ing the inflammatory response leading to anemia. Pathway 2: the 
innate immune system may aim to decrease the bioavailability of 
iron in order to prevent an expanding viral load in the acute-phase of 
the infection. This leads to the activation of hepcidin, sequestration 
of iron within cells, increased levels of ferritin and decreased hemo-
globin, culminating in hypoxia
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on the quality of the included studies. Despite most studies 
being of high quality, the data provided are mainly of cross-
sectional nature. Third, there was heterogeneity in the defi-
nition of moderate and severe cases of COVID-19 patients 
and in the definition of comorbid patients, which could have 
contributed to the observed heterogeneity in our meta-anal-
ysis. Finally, we cannot exclude the possibility that some 
study participants may overlap across the included studies. 
However, when randomly excluding 20% of studies from 
our analyses, or restricting the analyses to studies outside 
the Asia Pacific region, the results remained in line with the 
overall findings (Supplementary Tables S3-7). Also, some 
studies did not have a complete follow-up, and therefore our 
stratified analyses by the percentage of survivors should be 
interpreted with caution.
This meta-analysis suggests that hemoglobin and ferritin 
levels vary according to the severity of COVID-19 as well as 
age, gender and presence of comorbidity among COVID-19 
patients. Whether hemoglobin and ferritin can be used for 
prognostic purposes, or have further implications for iden-
tifying novel treatment targets, needs further investigation.
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